Payment overview · 2025
General Payments
$1,226.82
67 reported records · 21 companies
Healthcare provider profile · identity verified
Puneet Kumar Aggarwal, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · TAYLOR, MI · NPI 1649560798
Verified facts
What the public records show
CMS Open Payments records show Puneet Kumar Aggarwal, M.D. received $1,226.82 in general payments during 2025 across 67 reported records.
Novo Nordisk Inc accounted for 24.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $305.21 | 24.9% | 21 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $185.68 | 15.1% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $159.77 | 13.0% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $66.35 | 5.4% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $51.40 | 4.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $47.29 | 3.9% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $46.86 | 3.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $40.51 | 3.3% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $38.80 | 3.2% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $38.54 | 3.1% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $36.42 | 3.0% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $35.55 | 2.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.68 | 2.8% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.18 | 1.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $21.82 | 1.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.61 | 1.7% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $19.22 | 1.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.24 | 1.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.76 | 1.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.13 | 1.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.80 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,226.82 | 67 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $185.68 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $182.38 | 12 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $149.72 | 11 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $122.83 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $67.47 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $57.30 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $51.40 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $51.19 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $50.29 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $47.29 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $40.51 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $38.80 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $38.54 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $36.42 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $35.55 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $23.18 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $21.82 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $21.82 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.13 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.13 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 85 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 57 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
99 | 34 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
57 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
75 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
55 | 23 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
85 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
21 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 373 | 155 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 335 | 83 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 314 | 101 |
| Gabapentin | Gabapentin | 250 | 85 |
| Lisinopril | Lisinopril | 234 | 95 |
| Omeprazole | Omeprazole | 233 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 208 | 81 |
| Metformin Hcl | Metformin Hcl | 205 | 77 |
| Metoprolol Tartrate | Metoprolol Tartrate | 168 | 68 |
| Ibuprofen | Ibuprofen | 156 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 149 | 51 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 146 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 138 | 67 |
| Trazodone Hcl | Trazodone Hcl | 119 | 42 |
| Tizanidine Hcl | Tizanidine Hcl | 105 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 38 |
| Alendronate Sodium | Alendronate Sodium | 103 | 34 |
| Alprazolam | Alprazolam | 100 | 22 |
| Farxiga | Dapagliflozin Propanediol | 99 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 98 | 41 |
| Furosemide | Furosemide | 96 | 39 |
| Simvastatin | Simvastatin | 96 | 44 |
| Azithromycin | Azithromycin | 95 | 71 |
| Ropinirole Hcl | Ropinirole Hcl | 94 | 35 |
| Ondansetron Hcl | Ondansetron Hcl | 92 | 28 |
| Montelukast Sodium | Montelukast Sodium | 90 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 88 | 37 |
| Ozempic | Semaglutide | 85 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 85 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 82 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 79 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 39 |
| Jardiance | Empagliflozin | 75 | 26 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 74 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 74 | 34 |
| Tramadol Hcl | Tramadol Hcl | 71 | 28 |
| Ezetimibe | Ezetimibe | 69 | 20 |
| Buspirone Hcl | Buspirone Hcl | 66 | 25 |
| Dicyclomine Hcl | Dicyclomine Hcl | 62 | 22 |
| Pregabalin | Pregabalin | 62 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 22 |
| Meclizine Hcl | Meclizine Hcl | 58 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 28 |
| Trulicity | Dulaglutide | 55 | 23 |
| Diazepam | Diazepam | 53 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 26 |
| Sertraline Hcl | Sertraline Hcl | 53 | 23 |
| Allopurinol | Allopurinol | 50 | 16 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 47 | 15 |
| Lorazepam | Lorazepam | 45 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 45 | suppressed |
| Prednisone | Prednisone | 45 | 37 |
| Atenolol | Atenolol | 44 | 11 |
| Mirtazapine | Mirtazapine | 44 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 44 | suppressed |
| Famotidine | Famotidine | 43 | 25 |
| Sumatriptan Succinate | Sumatriptan Succinate | 43 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 41 | 20 |
| Baclofen | Baclofen | 40 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | 14 |
| Sucralfate | Sucralfate | 39 | 18 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 38 | suppressed |
| Carvedilol | Carvedilol | 38 | 18 |
| Fenofibrate | Fenofibrate | 38 | 14 |
| Clonazepam | Clonazepam | 37 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 36 | suppressed |
| Novolog Flexpen | Insulin Aspart | 36 | 13 |
| Losartan Potassium | Losartan Potassium | 35 | 19 |
| Meloxicam | Meloxicam | 35 | 17 |
| Naproxen | Naproxen | 35 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 35 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | 14 |
| Gemfibrozil | Gemfibrozil | 34 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 12 |
| Glipizide | Glipizide | 32 | suppressed |
| Potassium Chloride | Potassium Chloride | 32 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 32 | 19 |
| Clonidine Hcl | Clonidine Hcl | 31 | 12 |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 30 | suppressed |
| Topiramate | Topiramate | 30 | 12 |
| Fluconazole | Fluconazole | 29 | 12 |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 28 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Glimepiride | Glimepiride | 25 | 11 |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 24 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Eliquis | Apixaban | 21 | 12 |
| Linzess | Linaclotide | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Brilinta | Ticagrelor | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 17 |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Dutasteride | Dutasteride | 19 | 12 |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 11 |
| Varenicline Tartrate | Varenicline Tartrate | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 12 |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,226.82 · 67 records | Novo Nordisk Inc | AIRSUPRA, ARISTADA, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, ENTRESTO, FANAPT, FREESTYLE LIBRE 3, GEMTESA, LEQVIO, LYBALVI, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PAXLOVID, REPATHA, REXULTI, Rybelsus, SHINGRIX, SUBLOCADE, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, Wegovy, YUPELRI, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error